Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.
2.
3.

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, Milner R, Ali K, Barnard D, Bernstein M, et al.

Lancet. 1994 Sep 10;344(8924):703-7.

PMID:
7915773
4.

Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.

Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ.

J Pediatr. 1999 Jan;134(1):21-6.

PMID:
9880444
6.

FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.

Tanaka Y, Suzuki Y, Tsuge T, Kanamaru Y, Horikoshi S, Monteiro RC, Tomino Y.

Nephrol Dial Transplant. 2005 Nov;20(11):2439-45.

PMID:
16221721
7.

Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura.

Michel M, Kreidel F, Chapman ES, Zelmanovic D, Bussel JB.

Haematologica. 2005 Dec;90(12):1715-6.

8.

Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.

Shahgholi E, Vosough P, Sotoudeh K, Arjomandi K, Ansari S, Salehi S, Faranoush M, Ehsani MA.

Indian J Pediatr. 2008 Dec;75(12):1231-5. doi: 10.1007/s12098-008-0243-y.

PMID:
19190878
9.

Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action.

Lazarus AH, Freedman J, Semple JW.

Transfus Sci. 1998 Sep;19(3):289-94. Review.

PMID:
10351141
10.

Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study.

Monteleone PM, Vander Heyden MA, Steele DA, Kelleher JF.

Haematologica. 2000 Aug;85(8):887-8. No abstract available.

12.

[Use of anti-D (Rh) IgG or intramuscular polyvalent human immunoglobulin in the treatment of chronic autoimmune thrombocytopenic purpura].

Vizcaíno G, Diez-Ewald M, Arteaga-Vizcaíno M, Torres E.

Invest Clin. 1992;33(4):165-74. Spanish.

PMID:
1338940
13.

Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura.

Carcao MD, Blanchette VS, Wakefield CD, Stephens D, Ellis J, Matheson K, Denomme GA.

Br J Haematol. 2003 Jan;120(1):135-41.

PMID:
12492589
14.
16.

Mechanism of action of IVIG and anti-D in ITP.

Lazarus AH, Crow AR.

Transfus Apher Sci. 2003 Jun;28(3):249-55. Review.

PMID:
12725951
17.

Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.

Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, Bussel JB.

Blood. 2011 May 26;117(21):5723-32. doi: 10.1182/blood-2010-11-321398.

18.

A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).

O'Brien SH, Ritchey AK, Smith KJ.

Pediatr Blood Cancer. 2007 Feb;48(2):173-80.

PMID:
16550529
20.

FcγRIIa and FcγRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome.

Papagianni A, Economou M, Tragiannidis A, Karatza E, Samarah F, Gombakis N, Athanassiadou-Piperopoulou F, Vavatsi-Christaki N, Athanassiou-Metaxa M.

Blood Coagul Fibrinolysis. 2013 Jan;24(1):35-9. doi: 10.1097/MBC.0b013e328359bc3b.

PMID:
23249566
Items per page

Supplemental Content

Support Center